Predicted to enable DNA-binding transcription repressor activity, RNA polymerase II-specific and RNA polymerase II cis-regulatory region sequence-specific DNA binding activity. Predicted to be involved in cell differentiation; negative regulation of chondrocyte differentiation; and negative regulation of transcription by RNA polymerase II. Predicted to act upstream of or within several processes, including intestinal epithelial cell development; middle ear morphogenesis; and skeletal system development. Predicted to be active in nucleus. Orthologous to human NKX3-2 (NK3 homeobox 2).
RGD Description
Predicted to enable DNA-binding transcription repressor activity, RNA polymerase II-specific and RNA polymerase II cis-regulatory region sequence-specific DNA binding activity. Predicted to be involved in negative regulation of chondrocyte differentiation and negative regulation of transcription by RNA polymerase II. Predicted to act upstream of or within several processes, including intestinal epithelial cell development; middle ear morphogenesis; and skeletal system development. Orthologous to human NKX3-2 (NK3 homeobox 2); INTERACTS WITH bisphenol A; 17beta-estradiol (ortholog); 17beta-hydroxy-5alpha-androstan-3-one (ortholog).